Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
antibodies are low; This non-serious case was reported by a other health professional via call center representative and described the occurrence of therapeutic response decreased in a female patient who received HBV (Engerix B) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis and HBV (Engerix B) for prophylaxis. On an unknown date, the patient received the 3rd dose of Engerix B, the 2nd dose of Engerix B and the 1st dose of Engerix B. On an unknown date, an unknown time after receiving Engerix B, Engerix B and Engerix B, the patient experienced therapeutic response decreased (Verbatim: antibodies are low). The outcome of the therapeutic response decreased was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-FEB-2025 A surgery manager reported to have one employee who was ready for dental school. They gave her the series of Engerix-B vaccine two years ago in 2023 and the antibodies were low. The reporter enquired if she needs a booster.
Test Name: Hepatitis B surface antibody; Result Unstructured Data: (Test Result:low,Unit:unknown,Normal Low:,Normal High:) Low antibodies